Trinity Biotech Files Routine 6-K Report
Ticker: TRIB · Form: 6-K · Filed: Sep 30, 2024 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, routine-report
TL;DR
Trinity Biotech filed its monthly 6-K, standard procedure for foreign issuers.
AI Summary
Trinity Biotech plc filed a Form 6-K on September 30, 2024, reporting for the month of September 2024. As a foreign private issuer, the company is providing an update as required by SEC regulations. The filing does not contain specific financial figures or operational details beyond its routine reporting nature.
Why It Matters
This filing serves as a standard update for investors and regulators, confirming ongoing compliance and reporting for Trinity Biotech plc as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material financial or operational information.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- IDA Business Park Bray, County. Wicklow, Ireland (location) — Principal Executive Office
- September 2024 (date) — Reporting Period
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required by the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange.
What period does this specific 6-K filing cover?
This Form 6-K filing covers the month of September 2024.
Is Trinity Biotech plc required to file annual reports under Form 20-F or 40-F?
Yes, Trinity Biotech plc indicates it files annual reports under cover of Form 20-F.
Where are Trinity Biotech plc's principal executive offices located?
Trinity Biotech plc's principal executive offices are located at IDA Business Park, Bray, County Wicklow, Ireland.
Does this filing contain specific financial results or material new disclosures?
Based on the provided text, this filing appears to be a routine report and does not contain specific financial results or material new disclosures beyond its standard reporting requirements.
Filing Stats: 417 words · 2 min read · ~1 pages · Grade level 13.5 · Accepted 2024-09-30 15:07:36
Filing Documents
- zk2432085.htm (6-K) — 13KB
- 0001178913-24-003170.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ Louise Tallon Louise Tallon Chief Financial Officer Date: September 30, 2024